Exploring TPC2 as target for age-dependent macular degeneration therapy (P12)

• Subject Area: Pharmacology
• Term: since 2014
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 239283807

The endolysosomal two-pore channel 2 (TPC2) plays a key role in neovascularization and immune activation in the mouse model of laser-induced choroidal neovascularization (CNV) of age-related macular degeneration (AMD). Here, we will investigate the potential involvement of TPC2 in proliferative diabetic retinopathy. In addition, we will examine the effects of direct TPC2 activation on retinal neovascularization and immune activation. Finally, we will develop a gene therapy approach based on CRISPR/Cas9-mediated inactivation of Tpc2. Overall, the proposal aims at defining the therapeutic impact of TPC2 for the future treatment of AMD and related retinal disorders.

• DFG Programme: CRC/Transregios
• Subproject of: TRR 152: TRiPs to Homeostasis: Maintenance of Body Homeostasis by Transient Receptor Potential Channel Modules
• Applicant Institution: Ludwig-Maximilians-Universität München
• Project Heads: Professor Dr. Martin Biel; Professor Dr. Stylianos Michalakis, since 7/2022